Hematologic Oncology Articles

CLL Expert Explains Latest Treatment Developments in the Field
Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.
FDA Approves Brentuximab Vedotin for Frontline Hodgkin Lymphoma
The FDA has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma.
Ibrutinib, Venetoclax, and Obinutuzumab Triplet Safe, Effective as Initial CLL Therapy
Kerry A. Rogers, MD, discusses the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with chronic lymphocytic leukemia.
Fostamatinib Active in Chronic Immune Thrombocytopenic Purpura
Fostamatinib resulted in clinically meaningful, ongoing platelet responses and a low rate of bleeding events in 43% of patients with chronic immune thrombocytopenic purpura with long-disease duration. 
Hematopathologist Highlights Latest Developments in the Field
Nichon L. Grupka, MD, discusses advances in hematopathology, specifically mutations as prognostic indicators, disease-associated versus disease-causing mutations, and advice for physicians who are working to navigate the field.
IKZF1 Deletions Predict Poor Prognosis in Pediatric ALL
IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion (IKZF1plus) were associated with a dramatically reduced prognosis in pediatric patients with B-cell precursor ALL. 
Flinn Sheds Light on Advances in MCL and Other Lymphomas
Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.
Expert Highlights Game-Changing Therapies for Acute Leukemia
William Donnellan, MD, discusses recent FDA approvals for the treatment of patients with AML and ALL, and highlighted emerging agents in the pipeline.
Davids Discusses Frontline CLL Combo of Ibrutinib Plus Chemoimmunotherapy
Matthew S. Davids, MD, discusses the key results of ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy in CLL. 
Myeloma Expert Provides Insight on Practice-Changing Data
Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma. 
Publication Bottom Border
Border Publication